It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

VIRGILE

VIRGILE is a 3-year non-interventional, observational study designed to evaluate the effectiveness and tolerability of fingolimod in patients (N=1443) treated with fingolimod under real-world conditions in France, with up to 2 years of additional follow-up

Incidence of AEs and SAEs1

Virgile table-v2
Download pdf
border
Abbreviations
AE, adverse event; SAE, serious adverse event
Reference
1. Castelnovo G, et al. Poster presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 11- 13 September 2019, Stockholm, Sweden. P1388.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.